Articles On Paradigm Biopharmaceuticals (ASX:PAR)

The company continues to progress toward submission of the investigational new drug for Zilosul® and is focused on implementation of the osteoarthritis clinical program to support commercialisation.

Summary ASX 300-listed Paradigm Biopharmaceuticals disclosed ongoing data for Zilosul® treatment under the SAS. The drug development player is firmly focused on the IND submission for its OA treatment this quarter. Paradigm also highl...

It has been a positive day of trade for the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price. In morning trade, the biopharmaceutical company’s shares jumped 8% higher to $2.70. Why did the Paradigm share price jump higher? The catal...

In the 89 patients treated with Zilosul®, 75.3% reported at least a 25% reduction in WOMAC pain with 56.2% of patients reporting a greater than 50% reduction, while in subjects with knee OA, it shows a very consistent reduction in pain of n...

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceutical company is focused on repurposing the d...

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are jumping higher today after the company provided an update prior to market open this morning. At the time of writing, the Paradigm share price is trading 1.2% higher at $2.50. What’s dri...

Summary ASX-300 Paradigm Biopharmaceuticals has obtained FDA’s response in favour of its OA treatment. The Company is finalising to submit IND to the FDA during Q1 CY2021. Paradigm has commenced preliminary work for its Phase 3 clinic...

The S&P/ASX 200 Index (ASX: XJO) looks set to end the week in a disappointing fashion. In late morning trade the benchmark index is down a sizeable 0.75% to 6,706.3 points. Four shares that have fallen more than most today are listed b...

In morning trade the Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is climbing higher. At the time of writing, the biopharmaceutical company’s shares are up 2% to $2.59. Why is the Paradigm share price rising? Investors have been...

The same clinical trial protocol will be used in the US, Europe and Australia, potentially enabling registrations in multiple jurisdictions, saving time and money.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has come under pressure on Monday morning following the release of an update on its osteoarthritis (OA) clinical program. At the time of writing, the late stage drug development co...

The company is continuing the search for a person with extensive financial experience who will also be added to the board as an independent non-executive director.

The late-stage drug development company said the presentation would cover its proposed clinical program, safety and an update on other indications in the company’s R&D pipeline.

Summary ASX 300-listed Paradigm Biopharmaceuticals has started its Mucopolysaccharidosis type I (MPS-I) open-label Phase 2 clinical trial. The trial will assess the safety and tolerability of iPPS in MPS-I patients and will be conducted...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is climbing higher today on news the company has started Phase 2 trials of pentosan polysulphate sodium (iPPS). In early morning trade, the Paradigm share price is up 1.62% to $3.1...

The trial will be Paradigm’s first in MPS-I patients and will investigate treatment in a population, including pediatric patients.

Commercial head Beverley Huttmann, chief financial officer Justin Cahill and R&D scientist Catherine Stapledon bring skills and experience that further strengthen the capabilities of management as the company moves toward commercialisat...

Summary ASX 300 player Paradigm Biopharmaceuticals has reported additional positive data on patients who received Zilosul® under the Special Access Scheme (SAS) of the TGA. The Company anticipates providing information on further patien...

Pain reduction in 76 SAS patients (42 new patient data) being treated using the Phase 3 product are consistent with prior reports under TGA SAS.

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to bounce back strongly from yesterday’s surprise selloff. At the time of writing the benchmark index is up 1.35% to 5,894.3 points. Four shares that are climbing more...

01 Oct 2020 - Paradigm Biopharmaceuticals (ASX:PAR) report that patients receiving Zilosul reported a reduction in pain.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is charging higher again on Thursday. In morning trade the biopharmaceutical company’s shares are up a sizeable 9% to $2.89. This latest gain means the Paradigm share price is now...

Summary Paradigm Biopharmaceuticals’ supply agreement & exclusive licence with bene pharmaChem has been amended with positive & material commercial outcomes for bene pharmaChem is the only Pentosan Polysulphate Sodium (PPS) manuf...

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) is fighting hard to stay in positive territory. At the time of writing, the benchmark index is up slightly to 5,956.2 points. Four shares that are climbing more than most today...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been a very strong performer on Tuesday. In morning trade the biopharmaceutical company’s shares are up a sizeable 12% to $2.70. Why is the Paradigm share price surging higher?...

The exclusive supply of Pentosan Polysulphate Sodium for 25 years following marketing approval provides a greater level of commercial protection for Paradigm as it progresses towards commercialisation of Zilosul® in Europe.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) updated the market today on its phase III trial and product registration in Europe. The news shot the Paradigm share price 8.3% higher to $2.47 at the time of writing. In comparison, the All Ordin...

Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is slightly higher today, up 0.38% at the time of writing to $2.66. This came after the company released its annual report for the year ended 30 June 2020. What were the FY20 resul...

The ASX is littered with small-cap shares all vying to be global leaders in their fields. These innovative start-up companies seek to pursue untapped market opportunities that could one day bring them to stardom like industry giants CSL Li...

Paradigm’s investigation of PPS for MPS seeks to establish whether PPS may be an effective adjunct/combination therapy with current Enzyme Replacement Therapy treatments.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

On Wednesday I looked at three ASX shares that brokers have given buy ratings to this week. Unfortunately, not all shares are in favour with them right now. Three ASX shares that have just been given sell ratings by brokers are listed belo...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price rallied 9.6% in morning trade before pulling back to a gain of 0.9% at the time of writing. The rise in the Paradigm share price came after the company reported pain reduction in o...

Patients in the Expanded Access Program treated with Paradigm’s Phase 3 Zilosul® product was well tolerated with no serious Adverse Events reported.

It’s been a great day for Australian shares today, with the S&P/ASX 200 Index (ASX: XJO) up by 2.3% at the time of  writing. In particular, the biotech sector and the tech sector have been standout performers. Here we examine 4 ASX bio...

I believe ASX medical shares are among the most defensive on the market. After all, people require medical treatment regardless of the state of the economy. Despite the volatility seen in share markets as a result of COVID-19, the S&P/...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price climbed over 13% today before edging back to a more modest gain of 6% by the market’s close. The Paradigm share price increase came after the healthcare company revealed promising...

The company remains focused on its IND submission to the FDA for the remainder of 2020.

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) has followed the lead of U.S. markets and is on course to record a very strong gain. At the time of writing the benchmark index is up 1.2% to 6,011.2 points. Four shares that ar...

Bell Financial Group (ASX:BFG) is expecting to book a higher $23.5m first-half profit, but investors didn’t seem overly happy about it with shares dipping 5.2 per cent on Friday morning. The figure is 5 per cent up on the same period last y...

Dr Donna Skerrett has more than 30 years in the pharmaceutical industry and has been the company's chief medical officer since September 2019.

Paradigm is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.

Paradigm Biopharmaceuticals has been added to the S&P/ASX 300 Index while Alkane Resources, De Grey Mining, Legend Mining, Greenland Minerals and Salt Lake Potash are additions to the All Ordinaries index.

The company is preparing for phase-3 trials in both Osteoarthritis (OA) and Mucopolysaccharidosis (MPS).

Healthcare is not the favourite child it was at the start of the COVID-19 pandemic, but one index measuring the sector is still up on the wider market. Biotech Daily’s top 40 index is up 14 per cent over the last month, compared to 4 per ce...

The ASX is home to a small but vibrant and growing biotechnology sector. There are a number of providers that are making significant inroads on a global scale. Here we examine 3 ASX biotech shares that have all seen strong share price rise...

From the bulging file of Nasty Obscure Diseases we present idiopathic intracranial hypertension (IIH), a condition characterised by debilitating chronic daily headaches and in some cases severe vision impairment. It’s a poorly treated condi...